氟尿嘧啶与5-氟尿嘧啶在晚期胃肠道癌联合化疗中的比较。

Comparison of ftorafur with 5-fluorouracil in combination chemotherapy of advanced gastrointestinal carcinoma.

作者信息

Queisser W, Schnitzler G, Schaefer J, Arnold H, Drings P, Fritze D, Geldmacher J, Hartwich G, Herrmann R, Kempf P, König H, Meiser R J, Nedden R, von Oldershausen H F, Pappas A, Sievers H, Wahrendorf J, Westerhausen M, Witte S

出版信息

Recent Results Cancer Res. 1981;79:82-92. doi: 10.1007/978-3-642-81681-9_9.

DOI:10.1007/978-3-642-81681-9_9

PMID:6795701

Abstract

The aim of the study was to compare the combination 5-FU-carmustine with ftorafur-carmustine in the treatment of advanced gastrointestinal cancer. To this end, a prospective, multicenter, randomized trial was initiated. Part I of this trial showed that similar response rates can be obtained with 5-FU-carmustine and ftorafur-carmustine in 109 patients (32.7% versus 26.3%). However, median survival was better in patients treated with 5-FU-carmustine (307 days versus 163 days). Part II of the trial revealed that neither a higher dosage of ftorafur (2 g/m2/day X 5 days) nor the addition of vincristine to both regimens changed the previously obtained results significantly. Again, median survival was found to be better in patients treated with 5-FU combination chemotherapy (304 days versus 144 days). Both the 5-FU and the ftorafur combination were tolerated reasonably well. The results suggest that combination chemotherapy including 5-FU is superior to ftorafur at the applied dosages in terms of survival.

摘要

本研究的目的是比较5-氟尿嘧啶-卡莫司汀联合用药与替加氟-卡莫司汀联合用药在晚期胃肠道癌治疗中的效果。为此，开展了一项前瞻性、多中心、随机试验。该试验的第一部分显示，109例患者使用5-氟尿嘧啶-卡莫司汀和替加氟-卡莫司汀可获得相似的缓解率（分别为32.7%和26.3%）。然而，接受5-氟尿嘧啶-卡莫司汀治疗的患者中位生存期更长（307天对163天）。试验的第二部分表明，较高剂量的替加氟（2 g/m²/天×5天）或在两种治疗方案中添加长春新碱均未显著改变先前获得的结果。同样，接受5-氟尿嘧啶联合化疗的患者中位生存期更长（304天对144天）。5-氟尿嘧啶和替加氟联合用药的耐受性均较好。结果表明，在所应用的剂量下，含5-氟尿嘧啶的联合化疗在生存期方面优于替加氟。